SCHEMBL2836061

SCHEMBL2836061

COc1cc(C)c(S(=O)(=O)N2CCCC(Oc3ccnc(N4CCC(CCN5CCCCC5)CC4)n3)C2)c(C)c1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.35
LMNA P02545 3/20 0.34
CHRM4 P08173 1/20 0.34
GPR119 Q8TDV5 1/20 0.33
DRD3 P35462 3/20 0.33
DRD2 P14416 1/20 0.33
KDM4E B2RXH2 1/20 0.33
NAAA Q02083 1/20 0.33
CCR4 P51679 1/20 0.33
ACACB O00763 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
CYP19A1 P11511 1/20 0.32
HSP90AA1 P07900 1/20 0.32
HSP90AB1 P08238 1/20 0.32
HCRTR1 O43613 1/20 0.32
HCRTR2 O43614 1/20 0.32
HPGD P15428 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2835037 0.94 CHRM4 (0.36) ALDH1A1CHRM4GPR119DRD3DRD2
SCHEMBL2839410 0.86 ACACB (0.37) LMNAACACBGAAMAPTCYP19A1
SCHEMBL2834109 0.82 HTR7 (0.40) ALDH1A1CHRM4DRD3DRD2KDM4E
SCHEMBL2835296 0.81 HTR7 (0.40) ALDH1A1CHRM4DRD3DRD2KDM4E
SCHEMBL2836552 0.81 HTR7 (0.38) ALDH1A1CHRM4DRD3DRD2KDM4E
SCHEMBL2833758 0.81 HTR1A (0.37) DRD3DRD2ACACB
SCHEMBL2834917 0.80 LMNA (0.41) ALDH1A1LMNANAAAGAAMAPT
SCHEMBL2839870 0.80 HTR7 (0.38) ALDH1A1CHRM4DRD3DRD2KDM4E
SCHEMBL2840074 0.79 LMNA (0.35) ALDH1A1LMNACHRM4NAAAHCRTR1
SCHEMBL2834706 0.79 BDKRB1 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US claimed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds ADORA2B, CCNB1, TYMS ALDH1A1 2375/4885LMNA 3222/4885CHRM4 2247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.